TerminatedEarly Phase 1

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Stopped: Research Cancelled

United States6 participantsStarted 2012-12

Plain-language summary

This pilot clinical trial studies radioembolization and ipilimumab in treating patients with uveal melanoma with liver metastases. Radioembolization kills tumor cells by blocking the blood flow to the tumor and keeping radioactive substances near the tumor. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radioembolization together with ipilimumab may kill more tumor cells in patients with uveal melanoma

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologic diagnosis of metastatic uveal melanoma; the tumor biopsy/aspiration must be available for review * Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) * Patients must have liver metastasis * No more than one prior systemic therapeutic regimen; this includes chemotherapy, biologic therapy, biochemotherapy, or investigational treatment; this does not include any therapies given in the adjuvant setting * No concomitant therapy with any of the following: interleukin-2 (IL-2), interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids; must have been discontinued \> 4 weeks * Patients with prior hepatic embolization procedures are eligible as long as they are candidates for repeat procedures and they have demonstrated progressive disease * No infection with human immunodeficiency virus (HIV); due to the mechanism of action of ipilimumab, activity and side effects in an immune compromised patient are unknown * No active infection with hepatitis B * No active or chronic infection with hepatitis C * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Women must not be pregnant or breast-feeding due to unknown effects of treatments on the unborn fetus; all women of childbearing potential must have a blood test within 72 hours prior to randomization to rule out pr…

What they're measuring

Number of patients that experience grade 3-4 toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)

Timeframe: Up to 3 weeks after discontinuation of study treatment

Number of patients with an overall response of liver metastasis according to Response Evaluation Criteria in Solid Tumors (RECIST)

Timeframe: Up to 5 years

Overall survival

Timeframe: From the hepatic radioembolization procedure until death, assessed up to 5 years

Progression-free (PFS) survival according to Response Evaluation Criteria in Solid Tumors (RECIST)

Timeframe: From the hepatic radioembolization to confirmation of progression or death, assessed up to 5 years

Trial details

NCT IDNCT01730157

SponsorCase Comprehensive Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-02

View on ClinicalTrials.gov More Ciliary Body and Choroid Melanoma, Medium/Large Size trials